Genetics & Environmental Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics & Environmental Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Molecular Targets
Sangamo BioSciences Presents Postive Data Showing Pain Reduction by Novel ZFP Therapeutic at Society for Neuroscience Meeting
November 22nd, 2007
Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced the presentation of data demonstrating that treatment with a zinc finger DNA-binding protein (ZFP) Therapeutic targeting TrkA, a validated pain receptor, significantly reduced the perception of pain in a mouse model of bone cancer pain. The presentation of in vivo data from this novel therapeutic program was made at Neuroscience 2007, the 37th annual meeting of the Society for Neuroscience in San Diego. "These positive, proof of principle data highlight the potential for our ZFP technology in the treatment of chronic pain," commented Philip Gregory, D. Phil. Sangamo's vice president of research. "The TrkA-NGF pathway is...
Source: Genetics & Environmental Business Week (2007-11-22)
|
